The Global Inhaled Antibiotics Market Growth Accelerated By Adoption Of Inhaled Antibiotics For Treating Respiratory Infections

https://www.coherentmarketinsights.com/market-insight/inhaled-antibiotics-market-3980
Inhaled Antibiotics Market



Inhaled antibiotics are pharmaceutical drugs administered through inhalation to treat respiratory infections. They are delivered directly to the site of infection in the lungs, enabling higher drug concentrations at the target site with lower systemic drug levels and reduced side effects.

The global Inhaled Antibiotics Market is estimated to be valued at US$ 1,403.3 Mn in 2023 and is expected to exhibit a CAGR of 6.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends

Increased use of inhaled antibiotics allows for localized treatment of respiratory infections, decreasing systemic side effects usually associated with orally or intravenously administered antibiotics. This is a major driver of growth for the inhaled antibiotics market. Direct delivery of drugs to the site of infection leads to higher efficacy with lower drug dosage requirements. Growing prevalence of respiratory diseases such as cystic fibrosis and ventilator-associated pneumonia is further expected to support increased demand for inhaled antibiotics over the forecast period.

Segment Analysis

The global inhaled antibiotics market is dominated by the dry powder formulation segment, which accounted for around 69.2% of the total market share in 2023. Dry powder formulation provides direct lung delivery of drugs, ensuring better localization of antibiotics in the lungs and prevention of systemic effects. This makes dry powder formulations more effective than other forms for treating pulmonary infections.

Key Takeaways

The Inhaled Antibiotics Market Growth is expected to witness high growth over the forecast period of 2023 to 2030. The market is projected to grow at a CAGR of 6.7% during this period. By 2030, the market size is estimated to reach US$ 2,406.8 Mn.

Regional analysis
North America dominated the global inhaled antibiotics market in 2023 and is expected to continue its dominance over the forecast period. The high prevalence of respiratory diseases and presence of advanced healthcare infrastructure are driving the North America market. The Asia Pacific region is expected to witness the fastest growth owing to rising incidence of lung infections coupled with increasing healthcare expenditure in many developing nations in the region.

Key players
Key players operating in the inhaled antibiotics market include Gilead Sciences, Aradigm, Lupin Ltd., Polyphor, Insmed Incorporated, Pharmaero, Savara Pharmaceuticals. Gilead Sciences is a leading player with a strong product portfolio and global presence. Lupin Ltd. is another prominent generic drug manufacturer with a sizable market share in Asia Pacific and emerging markets.

Comments

Popular posts from this blog

Agricultural Micronutrients Market Growth Accelerated By Increasing Need For Improved Soil Fertility

Dairy Alternative Market Expected To Reach USD 26.01 Billion By 2023

Antimicrobial Additives Market Growth Accelerated By Rising Demand From End-Use Industries